The pursuit of a cure for Alzheimer's disease is becoming an increasingly competitive and contentious quest, with recent ...
The Brighterside of News on MSN
Experimental drug can sharply reduce amyloid beta's impact on Alzheimer’s
Early in Alzheimer’s disease, your brain can begin to change long before anyone notices a lost name or missed appointment.
Morning Overview on MSNOpinion
Top expert claims Alzheimer’s might not actually start in the brain
For more than a century, Alzheimer’s disease has been framed as a slow catastrophe that begins inside the brain and stays ...
Following the hard-won success of early anti-amyloid drugs, a new generation of Alzheimer’s modalities—from tau-targeting ...
7don MSN
Personalized prevention strategies may lower Alzheimer's risk by targeting individual factors
How can we influence whether we develop Alzheimer's disease later in life? Neurodegeneration researchers at the Institute for ...
Morning Overview on MSN
SciNeuro, Novartis strike $1.7B Alzheimer’s drug megadeal
Novartis has agreed to pay up to $1.7 billion to license an experimental Alzheimer’s therapy from China-based SciNeuro, a ...
ARIA is the most common side effect of anti–amyloid-beta MAB treatment. MABs increase vascular permeability, which can result in inflammation and leakage of proteinaceous fluid and blood products, ...
TORONTO -- An investigational antibody drug, designed to cross the blood-brain barrier (BBB) to eliminate amyloid-beta plaques associated with Alzheimer's disease, performed so well in a phase Ib/IIa ...
While amyloid β plaques are hallmarks of Alzheimer’s disease (AD), recent research suggests that they aren’t the only players in the neurodegenerative disorder. Genome-wide association studies and RNA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback